MRNA Starts 2026 Volatile: Examining Rally & Pullback, Outsized Options
•February 13, 2026
0
Why It Matters
The rally and outsized options activity signal that investors are betting on a 2026 earnings recovery, yet the FDA’s vaccine review refusal introduces regulatory risk that could cap upside and affect broader biotech sentiment.
Key Takeaways
- •Moderna shares up 5% after narrowing Q4 loss.
- •Revenue fell 30% YoY but 2026 rebound expected.
- •FDA declined to review new seasonal flu vaccine application.
- •Analysts raised price targets: RBC to $30, Jefferies to $37.
- •Options volume surged fivefold, indicating heightened speculative interest.
Summary
Market on Close highlighted Moderna’s volatile trajectory as the stock climbed 5% following a narrower fourth‑quarter loss and reaffirmed a 10% revenue‑growth goal for 2026. While revenue contracted 30% year‑over‑year, management signaled a rebound with future sales split evenly between the United States and overseas markets.
Technical analysis from lead market technician Rick Carter showed the stock up 32% over the past year, outpacing the broader health‑care sector, yet still respecting key resistance levels around $48‑$55 and support near $35‑$41. Analysts at RBC and Jefferies upgraded price targets to $30 and $37 respectively, reflecting optimism despite a recent FDA refusal to review Moderna’s new seasonal flu vaccine—a move that adds regulatory uncertainty to the company’s vaccine‑centric portfolio.
Options activity underscored the market’s mixed sentiment: daily volume spiked to 5.1 times the five‑day average, with roughly 170,000 contracts changing hands. The most active strikes were calls at $47 and $30 and puts at $45 and $35, while a notable opening trade involved 14,447 call contracts at a $3 debit, representing a $4.3 million bullish position.
For investors, the juxtaposition of a technical bounce, upgraded analyst forecasts, and heightened options flow suggests a short‑term upside bias, but the FDA setback and lingering sector‑rotation dynamics keep downside risk alive. Monitoring the $35‑$41 support corridor and upcoming earnings will be crucial as the market gauges whether Moderna can sustain its rebound amid regulatory headwinds.
Original Description
Moderna (MRNA) experienced a wild start to 2026, with shares nearly doubling before pulling back 20% from the recent 52-week high. Rick Ducat dives into technical trends to watch and the various support and resistance levels in the stock chart. As for the options flow, Rick talks about the massively outsized move traders experienced Friday.
======== Schwab Network ========
Empowering every investor and trader, every market day.
Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe
Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185
Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7
Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore
Watch on DistroTV - https://www.distro.tv/live/schwab-network/
Follow us on X – https://twitter.com/schwabnetwork
Follow us on Facebook – https://www.facebook.com/schwabnetwork
Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/
About Schwab Network - https://schwabnetwork.com/about
#moderna #healthcare #options #economy #finance #investing #marketnews #stock #stockmarket #trading #live #schwabnetwork #mrna #vaccine #health #chart #technicalanalysis
0
Comments
Want to join the conversation?
Loading comments...